Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bellus Health Inc (NQ: BLU )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Jun 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Bellus Health Inc

< Previous 1 2 Next >
BELLUS Health Inc. Announces Voting Results from Special Meeting of Shareholders
From BELLUS Health Inc.
Via Business Wire
BELLUS Health Inc. Calls Special Shareholders’ Meeting in Connection with GSK Acquisition
From BELLUS Health Inc.
Via Business Wire
BELLUS Health Reports First Quarter 2023 Financial Results and Business Highlights
From BELLUS Health Inc.
Via Business Wire
BELLUS Health Inc. (NASDAQ: BLU) Leading the Way in Tuesday Trading Based on Percentage Gain
Via Investor Brand Network
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ruth’s Inc. (Nasdaq – RUTH), Magenta Therapeutics, Inc. (Nasdaq – MGTA), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX)
From Brodsky & Smith LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. (Nasdaq – SPPI), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX), Univar Solutions Inc. (NYSE - UNVR)
From Brodsky & Smith LLC
Via GlobeNewswire
BELLUS Health Announces Meeting Updates
From BELLUS Health Inc.
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. (Nasdaq – SPPI), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX), Univar Solutions Inc. (NYSE – UNVR)
From Brodsky & Smith LLC
Via GlobeNewswire
GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health
From BELLUS Health Inc.
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX), Univar Solutions Inc. (NYSE - UNVR)
From Brodsky & Smith LLC
Via GlobeNewswire
BELLUS Health Announces Positive Results from its Phase 1 Bioavailability Equivalence Study Evaluating Once-Daily Extended-Release Formulation of Camlipixant in Comparison to Twice-Daily Immediate Release Formulation
From BELLUS Health Inc.
Via Business Wire
BELLUS Health Reports Year 2022 Financial Results and Business Highlights
From BELLUS Health Inc.
Via Business Wire
BELLUS Health to Participate in the Cowen 43rd Annual Health Care Conference
From BELLUS Health Inc.
Via Business Wire
BELLUS Health to Present on the Patient Experience and the Burden of Refractory Chronic Cough at the American Academy of Allergy, Asthma & Immunology Annual Meeting
From BELLUS Health Inc.
Via Business Wire
BELLUS Health Reports Third Quarter 2022 Financial Results and Business Highlights
From BELLUS Health Inc.
Via Business Wire
BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences
From BELLUS Health Inc.
Via Business Wire
BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the CHEST Annual Meeting
From BELLUS Health Inc.
Via Business Wire
BELLUS Health to Present at the H.C. Wainwright Global Investment Conference
From BELLUS Health Inc.
Via Business Wire
BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the European Respiratory Society International Congress 2022
From BELLUS Health Inc.
Via Business Wire
BELLUS Health Reports Second Quarter 2022 Financial Results and Business Highlights
From BELLUS Health Inc.
Via Business Wire
BELLUS Health Closes US$153 Million Public Offering of Common Shares in Canada and the United States
From BELLUS Health Inc.
Via Business Wire
BELLUS Health Announces Pricing of US$153 Million Public Offering in Canada and the United States
From BELLUS Health Inc.
Via Business Wire
BELLUS Health Announces the Launch of a Public Offering of Common Shares in Canada and the United States
From BELLUS Health Inc.
Via Business Wire
Bellus Health Announces Positive End-of-Phase 2 Meeting with the FDA and its CALM Phase 3 Program for BLU-5937 in Refractory Chronic Cough
From BELLUS Health Inc.
Via Business Wire
BELLUS Health to Participate in the William Blair Biotech Focus Conference
From BELLUS Health Inc.
Via Business Wire
BELLUS Health to Participate in the Jefferies Healthcare Conference
From BELLUS Health Inc.
Via Business Wire
BELLUS Health Reports First Quarter 2022 Financial Results and Business Highlights
From BELLUS Health Inc.
Via Business Wire
BELLUS Health to Present Late-Breaking Clinical Data from the Phase 2b SOOTHE Trial of BLU-5937 at the ATS 2022 International Conference
From BELLUS Health Inc.
Via Business Wire
BELLUS Health to Participate in Multiple Upcoming Investor Conferences
From BELLUS Health Inc.
Via Business Wire
BELLUS Health Reports Year 2021 Financial Results and Business Highlights
From BELLUS Health Inc.
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.